Crizlieva (Crizotinib Tablets IP 250 mg) is an anti-cancer medication that belongs to the class of tyrosine kinase inhibitors (TKIs). It is primarily used for the treatment of certain types of lung cancer by blocking abnormal proteins that promote the growth of cancer cells. Crizotinib works by inhibiting ALK (anaplastic lymphoma kinase), ROS1, and MET signaling pathways, thereby slowing or stopping the multiplication of cancer cells.
Crizlieva is an oral medication taken as directed by a healthcare professional, and treatment should be carried out under strict medical supervision.
Uses:
Crizlieva (Crizotinib) is used for the treatment of:
1. Non-Small Cell Lung Cancer (NSCLC)
- ALK-positive metastatic NSCLC
- ROS1-positive metastatic NSCLC
2. Other ALK-positive tumors
May be used in certain ALK-rearranged tumors as determined by a specialist.
Crizotinib helps slow cancer progression and improve quality of life in patients with gene-positive tumors.
Side Effects:
Common side effects may include:
- Nausea and vomiting
- Diarrhea or constipation
- Swelling (edema)
- Fatigue
-
Dizziness
- Changes in vision
- Elevated liver enzymes
- Loss of appetite
- Mild abdominal discomfort
Serious side effects can include:
- Severe liver toxicity
- Heart rhythm problems (QT prolongation)
- Pneumonitis (serious lung inflammation)
- Severe infection
- Kidney impairment
- Vision disturbances requiring prompt evaluation
- Low blood counts in some cases
Patients should be monitored regularly with liver function tests, ECG, kidney function, and blood tests during treatment.
Dosage:
To be taken only under medical supervision.
The exact dosage, frequency, and duration of therapy will be determined by your treating oncologist based on your medical condition, genetic test results (ALK/ROS1 status), and treatment response.
Do not self-administer or adjust the dose without medical advice.
Reviews
There are no reviews yet.